This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chelsea Therapeutics' Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Chelsea Therapeutics International Ltd. (CHTP)

2012 Wedbush PacGrow Life Sciences Management Access Conference Call

August 14, 2012 2:30 pm ET

Executives

Joseph G. Oliveto – Interim Chief Executive Officer

Analysts

Liana Moussatos – Wedbush Securities Inc

Presentation



Liana Moussatos – Wedbush Securities Inc

Okay, we are going to get started. I’m Liana Moussatos from Wedbush, and it’s our pleasure to have Joe Oliveto, CEO of Chelsea Therapeutics to give us a corporate update. Joe?

Joseph G. Oliveto

Thank you, Liana, and thanks to the Wedbush folks for inviting us today. Let’s see, great. First, just to remind you that we’ll be making the forward-looking statements I’ll direct you to the website where you can get our SEC filings, and we’ll get into the Northera droxidopa pitch. This slide, I’d like to remind people that well, the vast majority whatever we’ll be speaking about today is on our lead indication of neurogenic orthostatic hypotension and the company is very focused on neurogenic orthostatic hypotension. There’s a lot of legs behind droxidopa Northera for other indications, it’s on the market in Japan for Parkinson’s disease and intradialytic hypotension and (inaudible) studies at for fibromyalgia, ADHD and Parkinson’s Disease. So just want to leave you with the idea that there is a lot of opportunity for Northera once we get past the first hurdle for our lead indication.

Okay. So where is Northera? Northera is a prodrug of norepinephrine, it’s directly metabolized into norepinephrine, and it’s got a mechanism very similar or exactly similar to the way levodopa is converted, it’s a dopamine and that natural mechanism converting into norepinephrine the same endogenous of norepinephrine that you and I have in our bodies, so it lends itself to some safety advantages that you’ll see later on and it’s also the beneficiary of well documented safety and efficacy profile from being the market leader in Japan for the last couple of decades.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs